文献速递血栓与止血

阿哌沙班与利伐沙班、依诺肝素在急性肿瘤相关静脉血栓栓塞中的比较

Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
PubMed 文献 · Am J Hematol · 2019-08-19

该前瞻性队列研究在Mayo血栓形成门诊连续纳入750例急性肿瘤相关静脉血栓栓塞患者,分别接受阿哌沙班(n=224)、利伐沙班(n=163)或依诺肝素(n=363)治疗。三组VTE复发和大出血发生率相似,利伐沙班组CRNMB较高但死亡率较低。

要点

  • 阿哌沙班、利伐沙班和依诺肝素三组VTE复发和大出血发生率相似。
  • 利伐沙班组死亡率低于阿哌沙班组(HR 1.67,95%CI 1.20-2.33)和依诺肝素组(HR 0.73,95%CI 0.56-0.96)。

核心结论

  • 阿哌沙班、利伐沙班和依诺肝素三组VTE复发和大出血发生率相似;利伐沙班与较高的CRNMB但较低的死亡率相关。

研究设计与样本

  • 前瞻性队列研究,连续纳入2013年3月1日至2018年1月31日在Mayo血栓形成门诊治疗的750例急性Ca-VTE患者,其中阿哌沙班组224例、利伐沙班组163例、依诺肝素组363例。

主要发现

  • VTE复发:阿哌沙班组11例,利伐沙班组7例(阿哌沙班 vs 利伐沙班 HR 1.31,95%CI 0.51-3.36);依诺肝素组17例(阿哌沙班 vs 依诺肝素 HR 1.14,95%CI 0.54-2.42;利伐沙班 vs 依诺肝素 HR 0.85,95%CI 0.36-2.06)。
  • 死亡:阿哌沙班组82例,利伐沙班组74例(阿哌沙班 vs 利伐沙班 HR 1.67,95%CI 1.20-2.33);依诺肝素组171例(利伐沙班 vs 依诺肝素 HR 0.73,95%CI 0.56-0.96)。
  • 大出血:阿哌沙班组11例,利伐沙班组12例(阿哌沙班 vs 利伐沙班 HR 0.73,95%CI 0.32-1.66);依诺肝素组21例(阿哌沙班 vs 依诺肝素 HR 0.89,95%CI 0.43-1.84;利伐沙班 vs 依诺肝素 HR 1.23,95%CI 0.61-2.50)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To provide direct comparison between apixaban and rivaroxaban in patients with acute cancer-associated venous thromboembolism (Ca-VTE), consecutive patients treated with apixaban, rivaroxaban, or enoxaparin at Mayo Thrombophilia Clinic (March 1, 2013 to January 31, 2018)) were followed prospectively. The primary effectiveness outcome was venous thromboembolism (VTE) recurrence, and the secondary was mortality. The primary safety outcome was major bleeding, the secondary clinically relevant safety outcome was non-major bleeding (CRNMB), and the third a composite of major and CRNMB. There were 750 patients treated for acute Ca-VTE with apixaban (n = 224), rivaroxaban (n = 163), and enoxaparin (n = 363) within 14 days of diagnosis and for at least 3 months, or until study event. Recurrent VTE was diagnosed in 11 receiving apixaban, 7 receiving rivaroxaban (apixaban vs rivaroxaban hazard ratio (HR) 1.31, 95% confidence interval (95% CI) 0.51-3.36) and 17 in the enoxaparin receiving group (apixaban vs enoxaparin HR 1.14, 95% CI: 0.54, 2.42 and rivaroxaban vs enoxaparin HR 0.85, 95% Cl: 0.36, 2.06). There were 82 deaths in apixaban, 74 rivaroxaban (apixaban vs rivaroxaban HR 1.67, 95% Cl: 1.20, 2.33) and 171 in enoxaparin group (rivaroxaban vs enoxaparin HR 0.73, 95% Cl: 0.56, 0.96). Major bleeding occurred in 11 apixaban, 12 rivaroxaban (apixaban vs rivaroxaban HR 0.73, 95% Cl: 0.32, 1.66) and 21 enoxaparin group (apixaban vs enoxaparin HR 0.89, 95% Cl: 0.43, 1.84 and rivaroxaban vs enoxaparin HR 1.23, 95% Cl: 0.61, 2.50). The CRNMB rate was higher in rivaroxaban compared to apixaban (P = .03) and LMWH (P = .01) groups. Recurrence of VTE and major bleeding were similar in apixaban, rivaroxaban, and enoxaparin groups. Rivaroxaban was associated with higher CRNMB but lower mortality compared to apixaban and enoxaparin.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Wysokinski WE, Houghton DE, Casanegra AI, et al. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol. 2019. PMID: 31378995. doi:10.1002/ajh.25604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。